ArticleMedicine2025
Causality of blood metabolites and narcolepsy type 1: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolic disturbances have been implicated in narcolepsy type 1 (NT1), but the causal relationships between circulating metabolites and NT1 remain unclear. A two-sample bidirectional Mendelian randomization (MR) analysis was conducted to explore potential causal associations between 486 blood metabolites (7824 Europeans) and NT1. Genetic instruments were selected from large-scale genome-wide association study summary statistics under strict thresholds (P < 1 × 10-5, r2 < 0.001, F > 10). NT1 data were obtained from the R12 release of the FinnGen consortium. The inverse variance weighted method served as the primary estimator, complemented by MR-Egger regression, weighted median, heterogeneity, and pleiotropy assessments (including MR-Pleiotropy RESidual Sum and Outlier), and leave-one-out analysis. Reverse MR was performed to examine the potential effect of NT1 on metabolite levels. A total of 21 blood metabolites showed suggestive causal associations with NT1. Among the known metabolites, aspartate, 2-hydroxystearate, N-acetylglycine, and phenol sulfate were positively associated with NT1 risk, while indoleacetate, acetylcarnitine, caproate (6:0), docosapentaenoate (n3 DPA; 22:5n3), homostachydrine*, hydroquinone sulfate, 4-ethylphenylsulfate, 7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca), 4-androsten-3beta, 17beta-diol disulfate 2*, and 2-hydroxyglutarate exhibited inverse associations. Reverse MR analysis did not identify significant effects of NT1 on metabolite levels. This MR study identified multiple metabolites potentially associated with NT1, providing preliminary genetic evidence for the involvement of metabolic pathways in NT1 pathogenesis. These findings highlight the possible biological links between metabolic dysregulation and NT1 and lay a foundation for future large-scale and experimental studies to confirm their causal roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.